Lung Cancer
Conditions
Keywords
Screening
Brief summary
Co-design will be implemented to develop an innovative, Veteran-centered intervention (Vet Peer Connects program) that meets the needs of Black Veterans. Next, a feasibility pilot test of the Vet Peer Connects program will be conducted. The Peer will lead up to 5 group lung cancer screening orientations in community partner sites to reach up to 40 lung cancer screening eligible Black Veterans. The Peer will provide one-to-one tailored support to up to 15 Veterans (coaching, goal-setting, navigation to access Veterans Affairs lung cancer screening). Then, the study team will evaluate program delivery through ethnographic observation and field notes, Peer activity logs, and weekly check-ins between the study team and Peer. Investigators will interview Veteran participants, community partners, and lung cancer screening clinical staff to explore feasibility and acceptability of the Vet Peer Connects program and solicit suggestions for improvement. Preliminary data on the outcomes of the Vet Peer Connects program will be collected by study team through administering surveys to assess change in Social Cognitive Theory constructs, and extracting lung cancer screening uptake and tobacco treatment 3 months post enrollment from VA's Corporate Data Warehouse. This work will inform a subsequent multi-site stepped-wedge trial to assess effectiveness, implementation, and cost of the Vet Peer Connects program in VA lung cancer screening sites and neighboring branches of the National Association for Black Veterans.
Interventions
OTHERVeterans peer connect Program
To assess outcomes of the Peer-led program, the study team will collect information from Veteran pilot test participants via surveys and data abstraction on healthcare utilization (Lung cancer screening completion, tobacco treatment) from the Veterans Affairs Corporate Data Warehouse. Survey data will be collected at 3 timepoints: baseline, post-Peer-led orientation, and 3-months post-enrollment. Healthcare utilization data will be abstracted from the corporate data warehouse to reflect the 3-month post-enrollment timepoint. Finally, interviews will be conducted with a subset of participants.
Sponsors
VA Office of Research and Development
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Self-identified Black Veterans * Meet United States Preventive Services Task Force guidelines for lung cancer ( still smoking cigarettes or quit within past 15 years, greater than or equal to 20 pack-years total) * Have not yet undergone lung cancer screening
Exclusion criteria
* Non-Black Veterans
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lung Cancer Screening Uptake | 3 months | Electronic health record review on all enrolled subjects to determine if low dose chest CT for lung cancer screening occurred between the time of study enrollment and 3 months post-enrollment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tobacco Cessation Treatment | 3 months | Electronic health record review on all enrolled subjects to determine if the participant was provided tobacco cessation treatment, including nicotine replacement therapy, other pharmacotherapy, or referral for smoking cessation counseling, between the time of study enrollment and 3 months post-enrollment. |
| Stigma Related to Smoking | between 3-7 months post-enrollment, after completion of peer support intervention | Assess via qualitative interviews |
| Perceived Support From Peer | between 3-7 months post-enrollment, after completion of peer support intervention | Assess via qualitative interviews |
| Lung Cancer Screening Knowledge | 3 months | Assessed via survey measure: Knowledge of risks and benefits of lung cancer screening. Scale 0-18, higher score means a better outcome |
| Lung Cancer Screening Fatalism | 3 months | Assessed via survey measure: Adapted Illness Perception Questionnaire. Scale 10-50, higher score means better outcome |
| Trust in VA | 3 months | Assessed via survey measure: Adapted Modified trust scale for Veterans Affairs health system. New Scale 4-20, higher score means a better outcome |
| Lung Cancer Self-efficacy | 3 months | Assessed via survey measure: Lung cancer screening health belief self-efficacy scale. Scale 9-36, higher score means a better outcome |
| General Cancer Self-efficacy | 3 months | Assessed via survey measure: New General Self-efficacy scale. Scale 8-40, higher score means a better outcome |
| Intention to Engage in Shared Decision Making | 3 months | Assessed via survey measure: Preparation for Decision Making, scale 10-40, lower score means better outcome |
| Motivation to Quit Smoking | 3 months | Assessed via survey measure: Readiness to change smoking behavior, contemplation ladder, scale 1-10, higher score means a better outcome |
| Intention to Undergo Lung Cancer Screening | 3 months | Assessed via survey measure: Low Literacy Decisional Conflict Scale. Scale 0-9, higher score means a better outcome |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORRenda Wiener, MD
VA Boston Healthcare System, Boston MA
Participant flow
Recruitment details
We sought to recruit up to 40 Veterans that attended community events to learn more about lung cancer screening.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 3 |
| other Total, other adverse events | 0 / 3 |
| serious Total, serious adverse events | 0 / 3 |
Outcome results
None listed